Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli ...
Surmodics, Inc. (SRDX)
Last surmodics, inc. earnings: 4/29 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
surmodics.gcs-web.com/investor-overview
Company Research
Source: Business Wire
Addition of a low-profile device to the Surmodics Pounce™ thrombectomy platform allows for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the company’s Pounce™ LP (Low Profile) Thrombectomy System. The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with full commercial launch planned following completion of the LME.Surmodics’ Pounce Thrombectomy devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce LP Thrombectomy System is indicated for use in vessels ranging from 2 mm to 4 mm in diameter, sizes typical of vessels found below the knee. The Pounce
Show less
Read more
Impact Snapshot
Event Time:
SRDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRDX alerts
High impacting Surmodics, Inc. news events
Weekly update
A roundup of the hottest topics
SRDX
News
- Surmodics, Inc. (NASDAQ: SRDX) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $71.00 price target on the stock.MarketBeat
- Surmodics, Inc. (NASDAQ: SRDX) had its price target lowered by analysts at Needham & Company LLC from $47.00 to $43.00. They now have a "buy" rating on the stock.MarketBeat
- SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance [Yahoo! Finance]Yahoo! Finance
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceBusiness Wire
SRDX
Earnings
- 5/1/24 - Beat
SRDX
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 2/13/24 - Form SC
- SRDX's page on the SEC website